Equities research analysts forecast that NanoString Technologies, Inc. (NASDAQ:NSTG) will announce sales of $27.54 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for NanoString Technologies’ earnings. The highest sales estimate is $27.60 million and the lowest is $27.50 million. NanoString Technologies reported sales of $23.93 million in the same quarter last year, which suggests a positive year over year growth rate of 15.1%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 1st.

On average, analysts expect that NanoString Technologies will report full year sales of $27.54 million for the current fiscal year, with estimates ranging from $114.00 million to $115.11 million. For the next financial year, analysts anticipate that the company will report sales of $132.54 million per share, with estimates ranging from $123.00 million to $144.51 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for NanoString Technologies.

NanoString Technologies (NASDAQ:NSTG) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.17. NanoString Technologies had a negative net margin of 44.28% and a negative return on equity of 329.59%. The business had revenue of $34.59 million for the quarter, compared to analyst estimates of $29.87 million.

NSTG has been the topic of a number of research analyst reports. Cowen and Company restated a “buy” rating on shares of NanoString Technologies in a research note on Friday, July 14th. Zacks Investment Research upgraded NanoString Technologies from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Wednesday, July 5th. Morgan Stanley cut NanoString Technologies from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $23.00 to $20.00 in a research note on Thursday, April 20th. ValuEngine upgraded NanoString Technologies from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub cut NanoString Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. NanoString Technologies currently has an average rating of “Hold” and an average target price of $18.50.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its position in NanoString Technologies by 15.2% in the first quarter. Morgan Stanley now owns 1,886,772 shares of the biotechnology company’s stock valued at $37,490,000 after buying an additional 248,581 shares during the last quarter. Vanguard Group Inc. boosted its position in NanoString Technologies by 27.9% in the second quarter. Vanguard Group Inc. now owns 752,699 shares of the biotechnology company’s stock valued at $12,449,000 after buying an additional 164,141 shares during the last quarter. Russell Investments Group Ltd. boosted its position in NanoString Technologies by 1,452.0% in the second quarter. Russell Investments Group Ltd. now owns 538,792 shares of the biotechnology company’s stock valued at $8,910,000 after buying an additional 504,075 shares during the last quarter. RE Advisers Corp boosted its position in NanoString Technologies by 5.9% in the second quarter. RE Advisers Corp now owns 521,132 shares of the biotechnology company’s stock valued at $8,620,000 after buying an additional 29,132 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in NanoString Technologies by 6.8% in the first quarter. Wellington Management Group LLP now owns 509,051 shares of the biotechnology company’s stock valued at $10,115,000 after buying an additional 32,541 shares during the last quarter. Hedge funds and other institutional investors own 90.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/17/brokerages-expect-nanostring-technologies-inc-nstg-will-announce-quarterly-sales-of-27-54-million.html.

Shares of NanoString Technologies (NASDAQ:NSTG) opened at 13.87 on Thursday. NanoString Technologies has a 1-year low of $13.17 and a 1-year high of $23.45. The firm’s 50-day moving average is $15.53 and its 200-day moving average is $17.56. The firm’s market cap is $349.58 million.

About NanoString Technologies

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Get a free copy of the Zacks research report on NanoString Technologies (NSTG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.